Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...

the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine): Data were included for select countries based on EU ...

Vaccination is extremely crucial in reducing morbidity and mortality by protecting billions of people every year from infectious diseases. The key reason the adult population has grown significantly ...

Merck receives positive EU CHMP opinion for Capvaxive for pneumococcal vaccination in adults: Rahway, New Jersey Monday, February 3, 2025, 12:00 Hrs [IST] Merck, known as MSD outs ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

for Pneumococcal Vaccination in adults. The CHMP's recommendation is for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals ...